Drug Approval | March 02, 2022
Amneal enters U.S. biosimilars market with approval of Releukotm
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
The facility is spread across 215000 sq. feet and provides super-speciality care
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
The brand has added a range of exciting new products especially formulated for oily skin.
The speakers for the e-conference are: Dr. Mukund Chorgade, President/CSO, THINQ Pharma; Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Jayaseelan J., National Vice President (Industry Division), Indian Pharmaceutical Association; Spandan Mishra who is Director- Sales, Customer Service & Logistics for Evonik India, Nepal & Sri Lanka region; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR-IICT; Govind K. Jaju, Partner, Suingora Consulting; nd Pravin Prashant, Executive Editor, Indian Pharma Post & Editor, Indian Chemical News.
Funding to grow the insurance and digital therapeutics vertical in India
On track to complete the BLA submission in the first half of 2022
Singapore Health Sciences Authority (HSA) approval marks the first in a series of expected approvals of trodelvy in Asia
Pristyn Care operates on an innovative full- stack Care Delivery model to ensure that high quality surgical care is offered to patients at an affordable cost
Subscribe To Our Newsletter & Stay Updated
